Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

16

Revenue 2014

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer's Nexavar backed by NICE for liver cancer

Bayer's Nexavar backed by NICE for liver cancer

Bayer's Nexavar backed by NICE for liver cancer. The drug is the only approved first-line treatment for advanced HCC. ... At the list price, the twice-daily oral drug costs £128 per day per patient, but Bayer has agreed a drug at an undisclosed discount

EMA clears Bayer's Stivarga for liver cancer

EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer. The multikinase inhibitor will treat patients with HCC. ... PAH) therapy Adempas (riociguat) - that Bayer needs to drive its pharma unit as it digests Monsanto - bought for $66bn last September.

Novartis and Bayer among backers for European big data project

Novartis and Bayer among backers for European big data project Novartis and Bayer among backers for European big data project. The IMI's BigData@Heart programme will target cardiovascular research. ... The consortium is jointly led by Prof Diederick Grobbee from the University Medical Center Utrecht (UMCU) and Bayer

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids Bayer moves vilaprisan into phase III trials for uterine fibroids. ASTEROID study will investigate safety and efficacy of the novel drug. ... Bayer is beginning late-stage trials of vilaprisan, its novel oral, selective progesterone receptor modulator

COPD Life is Calling: Breaking Barriers for People Living with COPD Trapped in a Shrinking World

Bepanthen: Getting to the Bottom of Nappy Rash - by 3 Monkeys Zeno for Bayer.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Bayer
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
CNS revenue 2014
1: Pfizer
2: Biogen Idec
3: Novartis
4: Otsuka
5: Teva
6: Johnson & Johnson
7: Lilly
8: Merck KGaA
9: AstraZeneca
10: Shire
11: Bristol-Myers Squibb
12: UCB
13: Lundbeck
14: Eisai
15: GlaxoSmithKline
16: Sanofi
17: Mylan
18: Indivior
19: Actavis
20: Bayer
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Metabolic revenue 2014
1: Novo Nordisk
2: Sanofi
3: Merck & Co.
4: Lilly
5: AstraZeneca
6: Takeda
7: Novartis
8: Amgen
9: Bayer
10: Merck KGaA
11: Salix Pharmaceuticals
12: AbbVie
13: Dainippon Sumitomo Pharma
14: Kyowa Hakko Kirin
15: Mitsubishi Tanabe
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

The_Pharma_Wars_Series.png
The Pharma Wars Series
The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
What pharma marketers can learn from growth hacking?
Growth hackers instinctively blend technical skills with creative thinking...
Medicines for Europe
The sound of silence puts the squeeze on generics and biosimilars
Medicines for Europe vows to get governments talking to realise potential...

Infographics